Alphamab Oncology

Alphamab Oncology, founded in 2008 in Suzhou, China, develops oncology biologics. Its pipeline boasts Phase III bispecific antibodies KN026 (HER2) and KN046 (PD‑L1/CTLA‑4), the approved ENWEIDA (KN035) PD‑L1 drug, and ADCs JSKN003 and JSKN016 for HER2‑positive tumors.

Headquarters: China (CHN)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 484
HQ: Suzhou

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
9966	Alphamab Oncology Cap: 8.8B \| P/E: 33.5	EQUITY	HKG	HKD	KYG0330A1013	Active	📈